EGFR and non-small cell lung carcinoma: However, existing clinical research indicates that NSCLC patients with EGFR mutations have a poor response to EGFR-TKIs combined with PD-1/PD-L1 inhibitor immunotherapy, the toxicity reaction significantly increases.